Human study · Aging · 18 Nov 2026
In 514 people, a blood p-tau217 test matched spinal-fluid tests for amyloid plaques
Source: Nature Aging
What the research found
A diagnostic comparison in Alzheimer's disease was published online on 18 November 2026. It covered 514 people: a memory clinic (129), primary care (220), and a research cohort (165). The abstract does not give ages or a sex split. Lumipulse plasma p-tau217, and the ratio of p-tau217 to amyloid-beta 42, were compared with authorized spinal-fluid tests for amyloid plaques on a PET scan. Areas under the curve were 0.90 to 0.96. With one cutoff, accuracy was 83 to 91 percent for plasma p-tau217 and 83 to 92 percent for the ratio, against 88 to 90 percent for spinal fluid (all p at least 0.05). With two cutoffs, plasma p-tau217 accuracy was 90 to 97 percent, against 91 percent for spinal fluid in the clinical cohorts (adjusted p at least 0.12). The paper says this was in people who already had symptoms. A blood test compared with scans, not a treatment. DOI 10.1038/s43587-026-01259-z. Not medical advice.
Evidence level: Human study. A study in people, but an association isn't proof of cause.
More aging news
- In 138 older adults on ventilators, frailty did not line up with a long ventilation course
- In 1,464 older adults in China, a central systolic pressure of 130 mmHg matched the usual hypertension cutoffs on the same day
- In a Chinese aging cohort, a lower body roundness index lined up with higher odds of sarcopenia
- In 4,878 Medicare beneficiaries aged 65 and older, social frailty lined up with less participation and lower emotional well-being
- In two ageing cohorts, a higher long-run pulse pressure lined up with higher odds of sarcopenia